Cytophotometric DNA analysis of rectal mucosa of patients with ulcerative colitis

1985 ◽  
Vol 15 (4) ◽  
pp. 324-326 ◽  
Author(s):  
Hiroshi Suzuki ◽  
Shigeru Moriyama ◽  
Kazuaki Matsushima ◽  
Koichi Matsumoto ◽  
Keiji Iriyama
1985 ◽  
Vol 15 (6) ◽  
pp. 449-454 ◽  
Author(s):  
Hiroshi Suzuki ◽  
Eiichi Honda ◽  
Koichi Matsumoto ◽  
Keiji Iriyama

1992 ◽  
pp. 125-127
Author(s):  
M. G. Hartley ◽  
M. J. Hudson ◽  
M. J. Hill ◽  
A. E. Gent ◽  
R. H. Grace ◽  
...  

1988 ◽  
pp. 31-34 ◽  
Author(s):  
K. Inokuchi ◽  
H. Kuwano ◽  
K. Sugimachi ◽  
Y. Koga ◽  
M. Kitamura ◽  
...  

2020 ◽  
Vol 29 (14) ◽  
pp. 805-811
Author(s):  
Pineshwari Naeck-Boolauky ◽  
Jitka Adio ◽  
Jennie Burch

The gastrointestinal (GI) tract has a number of functions—ingestion, digestion, absorption and elimination. When the GI tract is working normally, it is efficient. However, this can change when disease, such as inflammatory bowel disease (IBD) occurs. IBD is a long-term relapsing and remitting autoimmune disease; it incorporates ulcerative colitis (UC). In UC, part or all the mucosa lining the rectum and colon becomes inflamed and ulcerated. UC that affects the rectum only is called proctitis. Effective treatment is essential. It is better to target the rectal mucosa directly in proctitis, using topical rectal medications in enemas or suppositories, as these have fewer side-effects and resolve symptoms more quickly than systemic drugs. However, patients may not feel clear about aspects of their IBD care and can find it difficult to initiate and comply with treatment and maintenance regimens. Nurses need to educate and support them to achieve optimal therapeutic outcomes in both the immediate and long terms.


1997 ◽  
Vol 40 (6) ◽  
pp. 718-725 ◽  
Author(s):  
Toshiaki Watanabe ◽  
Yoshiro Kubota ◽  
Tetsuichiro Muto

1990 ◽  
Vol 4 (7) ◽  
pp. 420-423 ◽  
Author(s):  
C Ó'Moráin ◽  
A Tobin ◽  
T McColl ◽  
Y Suzuki

Patients with active ulcerative colitis have increased levels of leukotriene B4 in their rectal mucosa. Eicosapentaenoic acid (EPA) competitively inhibits the cyclo-oxgenase pathway and reduces the formation of cyclo-oxygenase pathway products. EPA is a good substrate for lipoxygenase enzymes and is efficiently converted to leukotriene 85, which is less biologically active. The conversion of EPA to leukotriene B5 is as efficient as that of arachidonic acid to teukotriene B4. Two pilot studies showed benefit of EPA in the treatment of ulcerative colitis. Two of three controlled studies suggest that EPA is more effective than placebo in the treatment of active chronic ulcerative colitis. The mechanism of action is probably reduction of leukotriene B4, but EPA could increase cell and lysosomal membrane stability, or it may exert its effect by reducing interleukin-l. More controlled studies and detailed investigation into the mode of action of EPA are required.


2008 ◽  
Vol 134 (4) ◽  
pp. A-462
Author(s):  
Yakov Gitin ◽  
Francis A. Farraye ◽  
Xiaoling Zhang ◽  
Gang Liu ◽  
Avrum Spira ◽  
...  

Cancer ◽  
1984 ◽  
Vol 53 (12) ◽  
pp. 2683-2687 ◽  
Author(s):  
Keizo Sugimachi ◽  
Takeshi Okamura ◽  
Hiroshi Matsuura ◽  
Hiroko Ide ◽  
Mitsuo Endo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document